Icon (ICLR) Cash & Current Investments (2009 - 2026)
Icon's (ICLR) quarterly Cash & Current Investments came in at $928.4 million in Q2 2026, up 137.81% year-over-year from $390.4 million in Q2 2025, and up 21.33% quarter-over-quarter from $765.2 million in Q1 2026.
Analysis
Icon (ICLR) Cash & Current Investments (2009 - 2026) Analysis & Trends
Icon (ICLR) has reported Cash & Current Investments for 18 consecutive years, with $928.4 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Cash & Current Investments rose 137.81% year-over-year to $928.4 million in Q2 2026; TTM through Jun 2026 was $928.4 million, a 137.81% increase from a year earlier, with the FY2025 full-year figure at $729.3 million, up 22.22% from the prior year.
- Cash & Current Investments was $928.4 million for Q2 2026 at Icon, up from $765.2 million in the prior quarter.
- Over five years, Cash & Current Investments peaked at $928.4 million in Q2 2026 and troughed at $271.8 million in Q2 2023.
- A 5-year average of $520.2 million and a median of $516.6 million in 2024 frame the typical range for Cash & Current Investments.
- Across the five-year window, Cash & Current Investments slumped 58.52% in 2022 and surged 137.81% in 2026, its largest moves.
- Over 5 years, Cash & Current Investments stood at $321.4 million in 2022, then advanced by 18.25% to $380.1 million in 2023, then soared by 57.01% to $596.7 million in 2024, then grew by 22.22% to $729.3 million in 2025, then climbed by 27.29% to $928.4 million in 2026.
- The last three Cash & Current Investments figures came in at $928.4 million (Q2 2026), $765.2 million (Q1 2026), and $729.3 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Iqvia Holdings | 44.72 Bn | 42.64 Bn | 1.44 Bn | 2.08 Bn |
| 2 | Medpace Holdings | 17.37 Bn | 16.87 Bn | 201.64 Mn | 502.69 Mn |
| 3 | Icon | 13.65 Bn | 12.72 Bn | 479.29 Mn | 928.39 Mn |
| 4 | Charles River Laboratories International | 13.13 Bn | 12.94 Bn | 452.07 Mn | 192.03 Mn |
| 5 | Fortrea Holdings | 1.89 Bn | 1.72 Bn | 139.20 Mn | 168.60 Mn |
| 6 | Evotec SE | 574.75 Mn | 148.87 Mn | - | 425.88 Mn |
| 7 | Ginkgo Bioworks Holdings | 439.63 Mn | 355.09 Mn | 18.44 Mn | 84.54 Mn |
| 8 | Champions Oncology | 69.43 Mn | 65.03 Mn | 7.70 Mn | 4.40 Mn |
| 9 | MindWalk Holdings | 51.76 Mn | 46.29 Mn | 1.61 Mn | 5.47 Mn |
| 10 | VivoSim Labs | 1.37 Mn | 1.37 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 928.39 Mn |
| Mar 31, 2026 | 765.16 Mn |
| Dec 31, 2025 | 729.35 Mn |
| Sep 30, 2025 | 468.89 Mn |
| Jun 30, 2025 | 390.40 Mn |
| Mar 31, 2025 | 526.70 Mn |
| Dec 31, 2024 | 596.73 Mn |
| Sep 30, 2024 | 695.51 Mn |
| Jun 30, 2024 | 506.55 Mn |
| Mar 31, 2024 | 398.04 Mn |
| Dec 31, 2023 | 380.06 Mn |
| Sep 30, 2023 | 315.02 Mn |
| Jun 30, 2023 | 271.83 Mn |
| Mar 31, 2023 | 281.53 Mn |
| Dec 31, 2022 | 321.40 Mn |
| Sep 30, 2022 | 610.87 Mn |
| Jun 30, 2022 | 616.63 Mn |
| Mar 31, 2022 | 560.81 Mn |
| Dec 31, 2021 | 774.81 Mn |
| Sep 30, 2021 | 1.01 Bn |